BioSpace News Archive

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the pre-specified interim analysis of the RENOTORCH study has been completed.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 20th Association for Cancer Immunotherapy annual meeting being held on May 3-5, 2023, in Mainz.

ITM Isotope Technologies Munich SE announced that it has entered into a co-development and exclusive license agreement with the Paul Scherrer Institute, a leading Swiss research institute in the natural and engineering sciences, for the implementation of upscaled manufacturing of a novel therapeutic radionuclide, terbium-161.

Bionomics Limited announced that the Company has completed target enrollment of approximately 200 participants in its randomized, double-blind, placebo-controlled, multi-center Phase 2b ATTUNE clinical trial evaluating BNC210 in Post-Traumatic Stress Disorder.

Rockwell Medical, Inc. announced that its international partner, Drogsan Pharmaceuticals, submitted a Marketing Authorization application and GMP application for Triferic® AVNU to the Turkish Medicines and Medical Devices Agency, for which Drogsan received priority status and high priority status, respectively.

Eli Lilly and Company announced that tirzepatide achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.

Immunic, Inc. announced the appointment of Richard Rudick, M.D., a thought-leader in multiple sclerosis with decades of experience in the clinic, academia and industry, to its board of directors, effective April 26, 2023.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 13th C1-inhibitor Deficiency & Angioedema Workshop taking place in Budapest, Hungary from May 4-7.

Veru Inc. announced it will host a conference call and audio webcast on Thursday, May 11, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 second quarter financial results and provide a business update.

First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines.